Latest News

Thursday, May 25, 2017 | Medical Studies

Warby Parker Wants to Check Your Eyeglass Prescription with an App, But Some are Calling the Approach 'Dangerous'

Warby Parker, the $1 billion+ eyeglasses retailer, just launched an app that could make it easier to check your eyeglass prescription. The app, called Prescription Check, is meant to help people check…

Read the full story

Thursday, May 25, 2017 | Conferences

Housing, Meeting Registration Are Now Open for 2018 ASCRS Annual Meeting in Washington, D.C.

The ASCRS•ASOA Symposium & Congress is headed to Washington, D.C. during cherry blossom season in 2018 -- and housing and registration are now open. Are you planning to attend? If so, you&r…

Read the full story

Thursday, May 25, 2017 | Medical Studies

Putative Protective Role of Lutein and Zeaxanthin in Diabetic Retinopathy

DR remains one of the most debilitating complications of diabetes with a very heavy socioeconomic burden. Despite optimal control of blood glucose and advances in the treatment of diabetic eye disease…

Read the full story

Wednesday, May 24, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Roclatan

Aerie Pharmaceuticals reported the successful primary efficacy results of the company’s 90-day, phase 3 Mercury 2 registration trial for its fixed-dose combination product candidate, Roclatan. T…

Read the full story

Wednesday, May 24, 2017 | Conferences, ThromboGenics

ThromboGenics to present THR-317 Preclinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting

ThromboGenics announced that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary…

Read the full story

Wednesday, May 24, 2017 | Retina

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP

ProtoKinetix announced that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing. The stud…

Read the full story

Tuesday, May 23, 2017 | Acquisitions/Mergers

ClearSight Announces Sale of Parent Company, Sharklet Technologies

ClearSight LLC has announcd the acquisition of its parent company Sharklet Technologies by Peaceful Union, an equity medical device firm in Hangzhou, China. ClearSight LLC was co-founded by Drs. Kevin…

Read the full story

Tuesday, May 23, 2017 | Medical Studies, Glaukos Corporation

Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients

Glaukos announced that an analysis published in the Journal of Medical Economics evaluating various options for treating elevated IOP in open-angle glaucoma patients showed that two iStent Trabecular …

Read the full story

Tuesday, May 23, 2017 | Clinical Trials

Dompé Receives Positive CHMP Opinion in Europe For Oxervate for the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis

Dompé has announced that the Committee for Human Medicinal Products (CHMP) of EMA (European Medicines Agency) has released a positive opinion, recommending the marketing authorization for Oxerv…

Read the full story

Monday, May 22, 2017 | FDA Approval/Clearance, Genentech

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis

Genentech announced that the FDA has approved Actemra (tocilizumab) subcutaneous injection for the treatment of giant cell arteritis (GCA), a chronic and severe autoimmune condition. Actemra is the fi…

Read the full story

Monday, May 22, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Renu Advanced Formula Multi-Purpose Solution

Bausch + Lomb announced the launch of renu Advanced Formula multi-purpose solution for soft and silicone hydrogel contact lenses. The formula combines three disinfectants and two surfactants to provid…

Read the full story

Monday, May 22, 2017 | Earnings & Financials, Eyegate Pharmaceuticals

EyeGate Receives Milestone Payment from Valeant for EGP-437 for Postoperative Ocular Inflammation and Pain

EyeGate Pharmaceuticals announced that it has received its first development milestone from a subsidiary of Valeant under the company's license agreement with Valeant, pursuant to which EyeGate …

Read the full story

Monday, May 22, 2017 | Earnings & Financials, NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE

NovaBay Pharmaceuticals announced receipt of a letter from NYSE MKT LLC on May 16, 2017, stating that it is not in compliance with the continued listing standards (requiring stockholders’ equity…

Read the full story

Monday, May 22, 2017 | Medical Studies

High Vitamin K1 Intake Linked to Reduced Cataract Risk

María L. Camacho-Barcia, RD, from the University Hospital of Sant Joan de Reus in Spain, and colleagues examined the correlation between dietary vitamin K1 intake and the risk of incident catar…

Read the full story

Monday, May 22, 2017 | Medical Studies

Vision Impairment Among U.S. Preschoolers a Growing Problem

A growing number of U.S. children may develop vision problems before they reach kindergarten, according to a study that suggests eye screenings will become increasingly important for the preschool set…

Read the full story
Load More
 Stock Price  Change 
 ADVM $2.67  -2.91% 
 Aerie Pharmaceuticals, Inc. $54.40  34.32% 
 Akorn, Inc. $33.25  0.21% 
 Alimera Sciences, Inc. $1.43  -2.05% 
 Allergan $224.50  0.15% 
 Applied Genetic Technologies $5.47  2.24% 
 Bayer $130.85  -0.87% 
 Can-Fite Biopharma $1.77  1.14% 
 Clearside Biomedical $7.50  -0.53% 
 Cooper Companies, Inc. $218.52  0.39% 
 Eleven Biotherapeutics $1.48  11.28% 
 Escalon Medical Corp. $0.17  6.25% 
 Glaukos $39.93  -0.25% 
 Imprimis Pharmaceuticals, Inc. $3.40  -2.86% 
 Inotek Pharmaceuticals $1.75  -2.78% 
 IRIDEX Corporation $8.99  -0.44% 
 Johnson & Johnson $127.52  0.67% 
 Luxottica Group, S.p.A. $60.59  0.26% 
 Merck & Company, Inc. $65.05  0.18% 
 NovaBay Pharmaceuticals, Inc. $0.62  -3.13% 
 Novartis AG Common Stock $81.40  -0.05% 
 Ocular Therapeutix $10.30  0.68% 
 Ophthotech Corporation $2.32  -4.53% 
 Regeneron $455.77  -0.54% 
 Roche $34.35  0.38% 
 Second Sight Medical Products $1.17  -4.10% 
 Shire $184.94  -0.22% 
 STAAR Surgical Company $9.27  0.22% 
 TearLab Corporation $2.05  0.99% 
 Valeant Pharmaceuticals $12.80  -0.97% 
 Xoma $6.69  -0.74%